Background: Chemerin, a member of the adipokine family, plays a unique role in the inflammatory process of many chronic inflammatory diseases through modulating the synthesis of many inflammatory cytokines and the activity of some immune cells. This study aimed to clarify the possible role of serum chemerin in the pathogenesis and disease severity in patients suffering from psoriasis.

Objective: to look into the possibility that the adipokine chemerin might be a biomarker for psoriasis as it may be connected to the severity and pathophysiology of the condition.

Patients and methods: 45 psoriasis patients and 45 matched healthy controls were included. Using ELISA, serum chemerin levels were assessed in all participants along with a complete lipid profile. Psoriasis severity was investigated using the Psoriasis Area and Severity Index (PASI).

Results: Patients had a considerably higher serum chemerin level than controls (P <0.001). The PASI scores showed a positive correlation with chemerin levels (r =0.660, P =0.007). Compared to their matched controls, psoriasis patients had a statistically higher mean BMI (P <0.001). Higher TGs, TCs, and LDL in patients compared to controls were also indicative of a disordered lipid profile (P <0.001).

Conclusion: The fact that psoriasis patients have higher levels of chemerin than healthy controls raises the possibility that it might be influencing the course of the disease. Lipid profile results suggest that dyslipidemia may have contributed to its development, and chemerin may be a viable adipokine marker of the onset of metabolic syndrome in such patients.